Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biologic drug
|
| gptkbp:activeDuring |
golimumab
|
| gptkbp:administrativeDivision |
once a month
|
| gptkbp:brand |
gptkb:Simponi
|
| gptkbp:clinicalTrials |
Phase 3
GO-ALIVE GO-EXCEL GO-FURTHER GO-REVEAL |
| gptkbp:contraindication |
heart failure
active infections blood disorders serious infections liver problems history of hypersensitivity malignancies |
| gptkbp:date |
2013-04-24
|
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
TNF inhibitor
|
| gptkbp:firstAppearance |
2013
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:hasPopulation |
children
adults |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Simponi
|
| gptkbp:insuranceAccepted |
may require prior authorization
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count signs of infection |
| gptkbp:mandates |
active ankylosing spondylitis
active psoriatic arthritis moderate to severe rheumatoid arthritis moderate to severe ulcerative colitis |
| gptkbp:manufacturer |
gptkb:Janssen_Biotech
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:notableFeature |
gptkb:Humira
gptkb:Enbrel Remicade Cimzia |
| gptkbp:offers |
varies by region
|
| gptkbp:patentExpiration |
2028-04-24
|
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache nausea infections injection site reactions |
| gptkbp:storage |
store in refrigerator
|
| gptkbp:triggerType |
inhibits TNF-alpha
|
| gptkbp:type |
no
|
| gptkbp:usedFor |
treatment of ankylosing spondylitis
treatment of psoriatic arthritis treatment of rheumatoid arthritis treatment of ulcerative colitis |